Portfolio news

Basel, Switzerland - 11 December 2025, Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters…

Basel, Switzerland - 14 November 2025, Gibela Therapeutics GmbH (“Gibela”), the Basel-based Biotech focusing on the treatment of liver diseases using siRNA technology to target…

Basel, Switzerland - October 17, 2025, TOLREMO therapeutics AG (TOLREMO) today announced encouraging clinical data from 34 patients with advanced solid tumors treated with TT125-802…

Basel, Switzerland – Oct 15, 2025, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology…

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…

Basel, Switzerland – September 23, 2025 – metaLead Therapeutics AG (“metaLead”) announces the appointment of David Urech, PhD, Founder and former Chief Executive Officer of…

We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal. The company is…

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…

We’re excited to share our new partnership with BioDuro, a trusted CRDMO with a 29-year proven track record and strong reputation for delivering high-quality, end-to-end…

Our summer get-together brought people from across the biotech ecosystem, from founders and scientists, to investors, partners, and beyond, for an evening that combined meaningful…